Xencor (XNCR) Interest & Investment Income (2013 - 2026)
Xencor (XNCR) posted quarterly Interest & Investment Income of $5.5 million for Q1 2026, down 27.58% year-over-year from $7.5 million in Q1 2025, and down 11.95% quarter-over-quarter from $6.2 million in Q4 2025.
Analysis
Xencor (XNCR) Interest & Investment Income (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Interest & Investment Income for 10 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 27.58% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $25.4 million (down 17.71% YoY), while the FY2025 annual figure was $27.5 million, down 13.8% from the prior year.
- Interest & Investment Income slipped to $5.5 million in Q1 2026 per XNCR's latest filing, from $6.2 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $8.5 million in Q1 2024 and bottomed at $2.9 million in Q1 2023.
- Historically, Interest & Investment Income has averaged $6.8 million across 4 years, with a median of $7.4 million in 2024.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 194.86% — and 2026, when it retreated 27.58%.
- Xencor's Interest & Investment Income stood at $2.9 million in 2023, then surged by 181.61% to $8.2 million in 2024, then fell by 24.06% to $6.2 million in 2025, then slipped by 11.95% to $5.5 million in 2026.
- Business Quant data shows XNCR's Interest & Investment Income at $5.5 million in Q1 2026, $6.2 million in Q4 2025, and $6.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Xencor | 2.02 Bn | 1.64 Bn | - | 4.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.80 Mn |
| Mar 31, 2026 | 5.46 Mn |
| Dec 31, 2025 | 6.20 Mn |
| Sep 30, 2025 | 6.54 Mn |
| Jun 30, 2025 | 7.25 Mn |
| Mar 31, 2025 | 7.54 Mn |
| Dec 31, 2024 | 8.16 Mn |
| Sep 30, 2024 | 7.54 Mn |
| Jun 30, 2024 | 7.68 Mn |
| Mar 31, 2024 | 8.55 Mn |
| Mar 31, 2023 | 2.90 Mn |
| Jun 30, 2018 | 2.49 Mn |
| Mar 31, 2018 | 1.16 Mn |
| Dec 31, 2017 | 1.05 Mn |
| Sep 30, 2017 | 1.05 Mn |
| Jun 30, 2017 | 1.04 Mn |
| Mar 31, 2017 | 1.06 Mn |
| Dec 31, 2016 | 785,000.00 |
| Sep 30, 2016 | 579,000.00 |
| Jun 30, 2016 | 368,000.00 |